1. In Vivo

How To Decarbonize Pharma R&D

 
• By Francesca Bruce

As the planet heats up and sea levels rise, the need to reduce carbon emissions is becoming ever more urgent. The life sciences industry is just one of many that are looking to cut the carbon it produces.  

Climate Change
Regulators across the world should collaborate to design pathways that help decarbonize drug development • Source: Shutterstock

Drug manufacturing and supply chains may be more obvious targets for slashing emissions, but so too is R&D. Researchers should look to greater collaboration, adaptive trials and slashing “low value research,” among other things, to reach net zero targets, according to speakers at the 3 September Westminster Health Forum policy conference entitled “Next steps for decarbonization in the UK life sciences sector.”

Key Take Aways

  • R&D should also be a target for decarbonizing the life sciences sector.

Global warming is having a negative impact on health, for example, respiratory patients are suffering more exacerbations through deteriorating air...

More from ESG

More from In Vivo

EU Medtech Outlook: The View From MedTech Europe Experts

 
• By Ashley Yeo

MedTech Forum 2025 was less MDR-focused than in previous years, as macro issues and exogenous threats were forced further into the center of medtech business thinking.

‘Confident In Lorundrostat’s Promise’: Mineralys CEO Talks Trials And Next Steps

 
• By Sushmita Panda

In a conversation with In Vivo, CEO Jon Congleton discusses Mineralys’s data-rich journey toward an NDA filing, the significance of recent trial wins and how its candidate may offer a dual benefit in blood pressure and renal protection.

BioBytes: Qubit Pharmaceuticals Unveils Quantum AI Model For Drug Discovery

 
• By David Wild

Qubit Pharmaceuticals and Sorbonne University launched a quantum AI model that could slash drug synthesis requirements and enable exploration of previously undruggable targets.